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Abstract
Background: At diabetes diagnosis major decisions about life-style changes and treatments are made based on
characteristics measured shortly after diagnosis. The predictive value for mortality of these early characteristics is
widely unknown. We examined the predictive value of patient characteristics measured shortly after diabetes
diagnosis for 5-year all-cause and cardiovascular mortality with special reference to self-rated general health.
Methods: Data were from a population-based sample of 1,323 persons newly diagnosed with clinical diabetes and
aged 40 years or over. Possible predictors of mortality were investigated in Cox regression models.
Results: Multivariately patients who rated their health less than excellent experienced increased all-cause and
cardiovascular mortality. These end-points also increased with sedentary life-style, relatively young age at diagnosis
and presence of cardiovascular disease (CVD) at diagnosis. Further predictors of all-cause mortality were male sex,
low body mass index and cancer, while cardiovascular mortality increased with urinary albumin concentration.
Conclusions: We found that patients who rated their health as less than excellent had increased 5-year mortality,
similar to that of patients with prevalent CVD, even when biochemical, clinical and life-style variables were
controlled for. This finding could motivate doctors to discuss perceptions of health with newly diagnosed diabetic
patients and be attentive to patients with suboptimal health ratings. Our findings also confirm that life-style
changes and optimizing treatment are particularly relevant for relatively young and inactive patients and those
who already have CVD or (micro)albuminuria at the time of diabetes diagnosis.
Background
In observational studies several characteristics of
patients with type 2 diabetes have been linked to mor-
tality, most importantly age, sex, blood glucose level
[1-3], lipids [2], urinary albumin excretion [2,3], blood
pressure [2], smoking [2,3] and comorbidity like cardio-
vascular disease (CVD) [2,3]. In the general population
self-rated general health (SRH) predicts both future
morbidity such as ischaemic heart disease [4] and mor-
tality [5] independently of established risk indicators,
but evidence of this is scarce for people with diabetes
[3,6,7].
The findings in these studies are not unequivocal,
partly because patients were examined at different stages
in the natural history of diabetes [1,8]. In the Danish
study, Diabetes Care in General Practice, a large group
of people newly diagnosed with clinical type 2 diabetes
were examined by their general practitioner for the
most part within two weeks of diabetes diagnosis [9].
These patients have a considerable over-mortality com-
pared with the general population [10,11]. In this group
we investigated the contribution to 5-year all-cause and
cardiovascular mortality of the characteristics found at
the more or less acute state at diabetes diagnosis. In
particular, we evaluated the possible independent effect
of SRH on mortality. * Correspondence: olivarius@sund.ku.dk
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Study population
In the Diabetes Care in General Practice study [9], 474
general practitioners from 311 practices agreed to
include all subjects on their practice list who fulfilled
the following criteria: (1) newly diagnosed diabetes
based on hyperglycaemic symptoms and/or raised blood
glucose values; (2) diagnosed from 1 March 1989 to 28
February 1992; and (3) age 40 years or over. The diag-
nosis was subsequently confirmed with a single fasting
whole blood/plasma glucose ≥7.0/8.0 mmol/l measured
at a major laboratory. Accordingly, 1,381 diabetic
patients were included in the study, and a further 162
patients were excluded because of life-threatening
somatic disease (31%), severe mental illness (31%) and
unwillingness to participate (38%). Forty-six patients
being treated with steroids at the time of diagnosis and
12 non-Caucasian patients were excluded from the ana-
lysis. This gave a final study population of 1,323 diabetic
patients. A small number started insulin treatment
within 180 days of diagnosis, so 97.6% of these patients
were considered to have type 2 diabetes [9]. The Copen-
hagen and Frederiksberg Research Ethics Committee
approved the study.
Assessments
Immediately after diabetes diagnosis, the doctors
recorded the following information about the patient:
height and weight without shoes and outer garments;
blood pressure and heart rate by routine methods after
a 10-minute rest in a sitting position; sense of touch of
cotton wool and pin prick on both feet; presence of dor-
salis pedis or posterior tibial pulse on both feet; pre-
sence of patellar reflexes; history of myocardial
infarction and/or stroke causing hospitalization; and
amputation of any part of leg or foot before or at the
time of diabetes diagnosis. The median time (interquar-
tile range) from diagnosis until patients were examined
by their general practitioner was 12 (4-28) days, 10
(4-27) days for survivors and 12 (5-36) days for non-
survivors (p = 0.091). Retinopathy was assessed by prac-
tising ophthalmologists.
In questionnaires, patients gave information about the
preceding year’s leisure time physical activity in four
categories as shown in the Additional File 1. The three
non-sedentary categories were combined for the present
analyses because of small numbers (n =8 7i na l l )i nt h e
two most extreme categories. SRH was evaluated with a
single question: in general, how would you rate your
health at present? The response categories were excellent,
good, fair, poor and very poor. As above, the extreme
categories, poor (n = 103) and very poor (n =2 0 ) ,w e r e
combined for the present analyses. The SRH-question
was answered by 97.6% (1291/1323) of the patients. The
instruments for measuring physical activity and SRH
were chosen because they are internationally recom-
mended for health surveys [12,13]. Furthermore the
SRH-question is recommended especially for mortality
studies with a wide age range [14]. The patients were also
asked about whether they lived alone, their education,
and former or present cancer. These three questions and
the question concerning physical activity where devel-
oped by The National Institute of Public Health in Den-
mark for The National Health Interview Surveys. All five
questions (see Additional File 1) were tested for face and
content validity through two rounds of pilot interviews
preceded and followed by an expert hearing [15]. Infor-
mation about smoking habits, angina pectoris, and
intermittent claudication was collected with WHO-
standardised London School of Hygiene questionnaires
[16]. The entire patient questionnaire was pilot tested
among patients with known type 2 diabetes before the
study started.
Definitions
Cardiovascular disease (CVD) was defined as history of
myocardial infarction and/or history of stroke and/or
angina pectoris and/or intermittent claudication and/or
absent arterial pulses on both feet and/or amputation
on the lower extremities. Peripheral neuropathy was
defined as lack of a sense of pin prick and/or touch of
cotton wool on at least one foot and/or absent patellar
reflex on at least one knee. Diabetic retinopathy was
defined as presence of at least one microaneurysm or
further diabetic retinopathy.
Assays
Samples for diagnostic plasma or whole-blood glucose
tests were drawn after a minimum of 8 h fasting and
analysed at local major laboratories (n = 72). A factor of
1.15 was used to convert whole-blood measurements to
plasma glucose values. All remaining blood samples
were analysed at Odense University Hospital. Serum
total cholesterols were determined enzymatically with
cholesterol esterase-cholesterol oxidase-peroxidase
reagent and fasting serum triglycerides with a lipase-
glycerolkinase-glycerol-3-phosphate oxidase-peroxidase
reagent. Urinary albumin concentration was measured
in a freshly voided morning urine at Århus University
Hospital by a polyethylene glycol radioimmunoassay.
Quality assurance was obtained with commercial control
preparations.
Cause of death
The vital status was certified and surviving patients were
censored on 26 September 1995. The cause of death for
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on the death certificate from the electronic version of
the Danish National Death Register. The cause of death
was from the general practitioner in one case in which
it was not recorded in the register. The coding of cause
of death was validated with written information from
the general practitioners and by manually going through
copies of the original death certificates which could be
acquired for 296 patients. An autopsy had been done in
55 (18.6%) cases. The original entries were retained
because recoding of CVD as cause of death was only
relevant in one patient.
Of 292 patients with a registered manner of death, 281
died a natural death, 8 died from accidents and 3 from
suicide. The Danish National Death Register changed
coding of cause of death from ICD-8 to ICD-10 from 1
January 1994. The following ICD-8/ICD-10 codes were
used to classify cause of death: CVD, 390-458/I00-I99;
ischemic heart disease, 410-414/I20-I25; and stroke,
430-438/I60-I69. Diabetes mellitus was mentioned on
131 (44.3%) of 296 death certificates.
Statistical analysis
The influence on all-cause mortality of baseline charac-
teristics measured at diabetes diagnosis, i.e. socio-
demographic, clinical, biochemical and behavioural vari-
ables as well as complications and SRH, was investigated
in Cox proportional hazard regression models. In these
models the death intensity was represented as a function
of patient age, multiplicatively affected by the character-
istics, and patients entered the risk set at the time of
diagnosis. The effect of a characteristic was assessed by
a hazard ratio, i.e. the ratio of the age-specific mortality
rate in a specific category of a patient characteristic
compared with to the mortality rate in a reference cate-
gory. We chose to use age as time scale instead of dia-
betes duration, which is more common, because we
considered that the hazard changes more with age than
with diabetes duration [17]. In such analyses, a diagno-
sis-age effect compares the mortality hazards of those
d i a g n o s e da ta no l da g ev e r s u st h o s ed i a g n o s e da ta
younger age at each age, and a hazard ratio of e.g. 0.5
indicates that those diagnosed at an older age have half
the hazard of those diagnosed at a young age given that
they have the same age (and hence different diabetes
duration), i.e. the age-specific mortality hazard is lower
for those diagnosed at an older age relative to those
d i a g n o s e da tay o u n ga g e .W eu s e dt h eP R O CP H R E G
procedure from the SAS statistical package ver. 9.1.
We assessed the effects of the diagnostic characteris-
tics both separately and in multivariate models (Table
1). In three such models the aim was to assess the effect
of SRH while adjusting for possible confounding effects
of other characteristics. Model I adjusted for SRH and
all other baseline characteristics except chronic condi-
tions. Model II included all diagnostic characteristics
inclusive of chronic conditions. In model III, SRH was
omitted from model II to examine whether SRH
mediated the effect of the remaining characteristics on
mortality by comparing hazard rates with those in
model II. In a further analysis all interactions between a
characteristic and SRH, and the interaction between age
and sex, were added to model II. Akaike’s Information
Criterion (AIC) and Bayes’ Information Criterion (BIC)
were used to compare the quality of the models relative
to both fit and size [18]. When variables are added to a
model the model fit improves, and this improvement
has to be seen relative to the increase in model size.
The scores of AIC and BIC perform the trade-off, each
in a slightly different way, between the model likelihood
and the number of parameters in the model. The lowest
value of the information criterion indicates the model of
best quality. The effects of selected characteristics were
illustrated in Table 2 by the median life expectancy.
This was projected by model II through the 0.5-point of
the survival function [19].
In Table 3 the effects of the diagnostic characteristics
on cardiovascular mortality were studied, both in uni-
variate and multivariate models as in Table 1. In these
models, deaths from causes other than CVD were cen-
sored. In Table 4 a sub-group analysis of all-cause mor-
tality of relatively healthy patients was presented. In an
attempt to exclude the early effects of comorbidity on
general mortality, deaths occurring within the first 6
months after diabetes diagnosis were excluded in a sec-
ond sub-group analysis in Table 5. In Table 6 the all-
cause mortality experience within 3 years of diabetes
diagnosis or after this time was described. The propor-
tional hazard assumption was tested for model II by
adding the products of each covariate and log(time) to
all covariates in the model. The Wald chi-squared test
for all these products gives a test for proportional
hazard. See footnotes of Tables 1 and 3. The analyses of
effect heterogeneity in Table 6 also provided a test for
proportional hazards.
Results
Median age at diagnosis was 63.6 years for men and
67.5 years for women. After a median observation time
before death or censoring of 1904 days (range 11-2400
days), 298 (22.5%) patients had died, 100 (33.6%) from
ischemic heart disease, 30 (10.1%) from stroke, 34
(11.4%) from other cardiovascular morbidity, 68 (22.8%)
from cancer and 66 (22.1%) from other causes. The
total number of person-years in the study was 6447
(men: 3084, women: 3363).
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Page 4 of 12All-cause mortality
In univariate Cox regression models there was a trend of
increasing general mortality with decreasing SRH (Table
1). In the three multivariate models in Table 1 the predic-
tive value of urinary albumin, resting heart rate and smok-
ing became non-significant. Patients diagnosed at a young
age had a higher age-specific mortality than patients diag-
nosed at an older age, and male gender, low body mass
index and low level of physical activity also increased the
relative risk of death. SRH was still an important predictor,
but in model II no longer with any trend (Table 1, foot-
note f), and the effects of the three non-excellent cate-
gories of SRH did not differ in both model I and II (Table
1, footnote e). As expected, the models including chronic
conditions at diagnosis were better at predicting death
than the model without this information. At a 5% signifi-
cance level, SRH could not be removed from model II,
which contained all baseline characteristics. Removing
SRH from this model, however, changed the two informa-
tion criteria in different directions (model III in Table 1),
which could mean that the effect of SRH is less than
anticipated from the hazard ratios. The results from
model II were translated into estimated deviations from
the estimated life expectancy in Table 2.
Cardiovascular mortality
The analyses from Table 1 were replicated for cardiovas-
cular mortality (Table 3) for which urinary albumin was
Table 2 Estimated life expectancy of newly diagnosed
type 2 diabetic patients according to characteristics at
diagnosis
Age at diabetes diagnosis (years)
Men Women
40 60 80 40 60 80
Life expectancy (years) 59.3 75.1 91.2 60.0 76.9 93.3
Estimated deviation from life expectancy (years)
Self-rated health
Excellent 000000
Good -4.3 -2.8 -3.2 -2.1 -3.0 -4.1
Fair -4.3 -2.8 -3.3 -2.1 -3.0 -4.1
Poor/very poor -3.7 -2.2 -3.0 -1.2 -2.9 -3.5
Physical activity
Active 000000
Sedentary -1.9 -1.3 -2.4 -0.7 -1.7 -2.1
Cardiovascular disease
N o 000000
Yes -2.3 -2.1 -2.7 -1.2 -2.9 -3.5
Values are median life expectancy (years) and deviations from median life
expectancy (years) according to baseline characteristics calculated from Model
II which includes all baseline characteristics. The other factors in the model
are kept fixed at either the baseline comparison category (categorical
variables) or the median baseline value for the survivors in Table 1
(continuous variables). Physical activity and SRH were related (p < 0.0001), but
none of the examined interaction terms was statistically significant, so the
estimated effects in the table are additive.
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Page 6 of 12a statistically significant predictor. SRH and physical
activity both had approximately the same hazard ratios
as in the multivariate models with all-cause mortality.
Additional analyses
The question of inter-rater variability was analysed as a
case of clustering. A model like model II from Table 1,
where a robust sandwich estimator for the covariance
matrix was used to account for clustering, gave the fol-
lowing hazard ratios for good, fair and poor/very poor
SRH, respectively: 2.46 (1.22;4.97), p = 0.012; 2.51
(1.24;5.05), p = 0.010; and 2.16 (0.99;4.71), p = 0.053. I.e.
we found no evidence that inter-observer variability has
influenced the results.
As SRH may be related to renal threshold and pre-
sence of symptoms, we added urinary glucose at diagno-
sis (linearly, p = 0.78) and number of 16 specified
s y m p t o m sa td i a g n o s i s( 0 ,1 ,2 ,3 ,a n d4o rm o r es y m p -
toms, p = 0.93)[20] to model II (Table 1). This analysis
gave the following hazard ratios (95%-confidence inter-
vals) for good, fair and poor/very poor SRH, respec-
tively: 2.42 (1.26;4.64), p = 0.0081; 2.50 (1.32;4.73), p =
0.0050; and 2.16 (1.04;4.49), p = 0.040. I. e. the associa-
tion between SRH and mortality was virtually
unchanged.
A sub-group analysis of relatively healthy persons was
done (Table 4) as well as an analysis of deaths occurring
within 3 years of diabetes diagnosis and after this time
(Table 6). Hazard ratios for physical activity and SRH
were not lessened when the analysis was restricted to
either healthy persons or later deaths. In multivariate
analyses excluding early deaths, the hazard ratios were
by and large unchanged from Table 1 (Table 5). None
of the interactions of the covariates with SRH added to
model II in Table 1 were significant after Bonferroni
correction (Table 6).
Discussion
Our patients are likely to be representative of the gen-
eral population of patients with newly diagnosed clinical,
symptomatic diabetes in this age group because of the
well-defined background population in each general
practice, the unchanged inclusion activity during the
inclusion period, and the small number of exclusions
[9]. Six years after diagnosis, only 17% of the surviving
patients had ever been treated at a diabetes clinic [9],
and we suggest that our study reflects results obtained
in the general population of type 2 diabetic patients
rarely seen in secondary care. Studies including patients
with known diabetes may be misleading because of
selective survival of patients with a more favourable risk
factor profile [8]. Furthermore, in studies including
patients with known diabetes, SRH may be the result of
living with restrictions and treatments. The high
T
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Page 7 of 12mortality rate in the present study must be viewed in
light of the fact that patients were included with no
upper age limit.
SRH is known to be associated with mortality and
morbidity in the general population [4,5,21,22], while
evidence of these associations is only slowly emerging
for people with type 2 diabetes [3,6,7]. A large study
with 2.4 years of follow-up used the EuroQol visual ana-
logue scale (VAS) for self-rated health and found that a
10-point higher VAS score was associated with a 6%
lower risk of vascular events [6]. We found that patients
who rated their health as less than excellent had
increased 5-year mortality, similar to that of patients
with a history of CVD already at diabetes diagnosis
(Table 2). The high response rate for our SRH-question
(97.6%) indicates that the question was meaningful for
the respondents, and it may be that the results from an
ordinal scale with 5 categories are easier to use in the
doctor-patient encounter than the results from a VAS
scale.
What does SRH actually measure? Responders’
grounds for rating their health probably represent a per-
sonal estimation of longevity [21], which may be done
by accounting for current or previous physical health,
symptom perception, personal resources and physical
functioning [23,24] together with health behaviour
Table 4 Vital status 5 years after diabetes diagnosis and Cox models in a sub-group of healthy
a patients
Hazard ratio
Survivors
n = 595
Deceased
n = 101
Univariate
analysis
Multivariate model
II
b
Multivariate model
III
b
Sex Women 294 (49) 39 (39) 1 1 1
Men 301 (51) 62 (61) 1.96 (1.30-2.94)** 2.32 (1.29-4.19)** 2.23 (1.25-3.99)**
Age at diabetes diagnosis (years) 61.1 (51.8-
70.0)
71.5 (62.9-
77.4)
0.95 (0.85-1.08) 0.81 (0.70-0.93)** 0.81 (0.70-0.93)**
Living alone No 421 (73) 60 (63) 1 1 1
Yes 157 (27) 36 (38) 0.87 (0.55-1.36) 1.04 (0.57-1.90) 1.03 (0.57-1.87)
Education Higher 139 (24) 14 (15) 1 1 1
Basic 429 (76) 77 (85) 1.26 (0.70-2.25) 1.48 (0.73-3.02) 1.50 (0.74-3.05)
Diagnostic plasma glucose
(mmol/l)
c
13.7 (10.8-
17.1)
14.7 (10.9-
17.9)
1.26 (0.71-2.23) 1.15 (0.60-2.20) 1.17 (0.61-2.25)
Fasting triglycerides (mmol/l) 1.87 (1.30-
2.87)
1.88 (1.37-
2.83)
1.04 (1.00-1.07)* 0.99 (0.89-1.10) 1.00 (0.90-1.10)
Total cholesterol (mmol/l) 6.2 (5.5-7.1) 6.1 (5.1-7.1) 0.99 (0.88-1.13) 1.00 (0.82-1.23) 1.00 (0.81-1.22)
Urinary albumin (mg/l)
ac 10.5 (5.3-21.7) 12.6 (7.2-28.7) 1.16 (0.97-1.40) 1.05 (0.84-1.32) 1.06 (0.85-1.32)
Body mass index (kg/m
2) 29.1 (26.0-
33.2)
28.4 (26.3-
31.5)
1.00 (0.96-1.04) 1.00 (0.94-1.05) 1.00 (0.95-1.05)
Resting heart rate (beats/min)
d 76 (68-80) 76 (72-84) 1.20 (1.01-1.42)* 1.03 (0.83-1.27) 1.02 (0.83-1.27)
Systolic blood pressure (mmHg)
d 150 (130-160) 155 (140-170) 1.06 (0.96-1.17) 1.12 (1.00-1.26) 1.13 (1.00-1.27)*
Physical activity Active 476 (83) 61 (64) 1 1 1
Sedentary 100 (17) 35 (36) 1.75 (1.13-2.71)* 1.53 (0.87-2.68) 1.66 (0.97-2.86)
Smoking Never 193 (34) 33 (34) 1 1 1
Former 180 (32) 25 (26) 1.08 (0.64-1.83) 0.94 (0.48-1.81) 0.94 (0.49-1.82)
Current 192 (34) 38 (40) 1.93 (1.18-3.16)** 1.58 (0.84-2.98) 1.59 (0.86-2.97)
Self-rated health
ef Excellent 95 (16) 6 (6) 1 1
Good 229 (40) 34 (35) 1.43 (0.72-2.85) 2.16 (0.82-5.69)
Fair 226 (39) 47 (50) 1.69 (0.87-3.27) 2.30 (0.87-6.05)
Poor/Very
poor
29 (5) 9 (9) 2.30 (0.94-5.61) 2.10 (0.58-7.57)
Values of characteristics at diabetes diagnosis are numbers (%) or medians (95%-confidence intervals). Hazard ratios (95%-confidence intervals) and p-values are
from univariate and multivariate Cox regression analyses.
a This relatively healthy sub-group was defined as those patients without the following conditions at diabetes diagnosis: CVD, diabetic retinopathy, peripheral
neuropathy, cancer and urinary albumin concentration ≥ 200 mg/l.
b As in Table 1 and 3
c The characteristic is log-transformed in the analysis
d Hazard ratio estimates risk increase per 10 units of the characteristic
e Wald test for the equality of the three self-rated health effects: p-value = 0.71 (model II)
f Trend test including the SRH variable as a continuous variable in the multivariate regression analysis: p-value = 0.078 (model II)
* p < 0.05, **p ≤ 0.01, ***p ≤ 0.001
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Page 8 of 12[23,24], comparison with the health of age peers [24],
and a knowledge of familial dispositions [21]. Until now
there is only weak evidence to suggest that mental states
affect clinical outcomes independently of conventional
risk factors [25]. In the present analyses a clear trend of
increasing mortality with decreasing SRH was observed
univariately (Table 1), but after multivariate adjustment
with all available possible confounders the three non-
excellent SRH categories were no longer different (Table
1, Model II, footnote e). This means that in these
patients newly diagnosed with diabetes the effect of
SRH boils down to whether their health is considered to
be excellent or not. It seems reasonable to assume that
SRH carries risk information which cannot fully be
uncovered by the clinical information available at dia-
betes diagnosis. The possibility of residual confounding,
however, cannot be ruled out and it is probable that
these unknown confounders to a considerable degree
have a biological basis [22,26].
Physical inactivity has been found to be an indepen-
dent predictor of mortality in people with known type 2
diabetes with risk ratios similar to those of our newly
diagnosed patients [27]. In contrast to the situation with
SRH, etiological knowledge supports a causal role of
Table 5 Predictors of all-cause mortality in patients who died later than 6 months after diabetes diagnosis
Model I Model II Model III
Information criteria, AIC/BIC 1934.1/1991.6 1907.5/1978.5 1911.4/1972.2
Sex Women 1 1 1
Men 1.66 (1.19-2.30)** 1.63 (1.16-2.28)** 1.60 (1.14-2.23)**
Age at diabetes diagnosis (years) 0.85 (0.77-0.93)*** 0.82 (0.75-0.90)*** 0.82 (0.75-0.90)***
Living alone No 1 1 1
Yes 1.23 (0.90-1.68) 1.28 (0.94-1.74) 1.28 (0.94-1.74)
Education Higher 1 1 1
Basic 1.12 (0.76-1.65) 1.16 (0.79-1.71) 1.18 (0.81-1.74)
Diagnostic plasma glucose (mmol/l)
a 0.96 (0.64-1.43) 1.07 (0.71-1.59) 1.09 (0.73-1.63)
Fasting triglycerides (mmol/l) 0.97 (0.90-1.04) 0.98 (0.91-1.06) 0.98 (0.91-1.06)
Total cholesterol (mmol/l) 0.96 (0.85-1.08) 0.93 (0.82-1.04) 0.92 (0.82-1.04)
Urinary albumin (mg/l)
a 1.09 (0.98-1.20) 1.09 (0.98-1.20) 1.08 (0.98-1.19)
Body mass index (kg/m
2) 0.97 (0.94-1.00)* 0.97 (0.94-1.00)* 0.97 (0.94-1.00)*
Resting heart rate (beats/min)
b 1.07 (0.96-1.20) 1.08 (0.96-1.21) 1.09 (0.97-1.21)
Systolic blood pressure (mmHg)
b 1.04 (0.97-1.11) 1.06 (0.99-1.14) 1.07 (1.00-1.15)*
Physical activity Active 1 1 1
Sedentary 1.71 (1.26-2.33)*** 1.66 (1.23-2.25)*** 1.62 (1.20-2.17)**
Smoking Never 1 1 1
Former 1.38 (0.95-1.99) 1.32 (0.91-1.93) 1.35 (0.93-1.96)
Current 1.22 (0.82-1.82) 1.25 (0.83-1.87) 1.25 (0.83-1.87)
Self-rated health
c Excellent 1 1
Good 2.60 (1.36-4.97)** 2.45 (1.28-4.70)**
Fair 2.87 (1.53-5.37)*** 2.35 (1.25-4.43)**
Poor/Very poor 2.84 (1.39-5.83)** 2.03 (0.98-4.22)
Cardiovascular disease No 1 1
Yes 2.17 (1.62-2.90)*** 2.27 (1.71-3.00)***
Diabetic retinopathy No 1 1
Yes 1.21 (0.69-2.13) 1.16 (0.66-2.04)
Peripheral neuropathy No 1 1
Yes 0.92 (0.66-1.29) 0.95 (0.68-1.33)
Cancer (former or present) No 1 1
Yes 2.28 (1.40-3.73)*** 2.26 (1.39-3.68)**
Values are hazard ratios (95% confidence intervals) with p-values from 3 multivariate Cox regression analyses with and without self-rated health and/or
complications at diabetes diagnosis. Deaths occurring within 6 months of diabetes diagnosis (n = 25) were excluded from this analysis, which comprised 273
deceased and 1,025 survivors. These multivariate analyses are based on 1,101 entries without missing values in any of the three models; n for survivors/deceased
= 884/217.
a The characteristic is log-transformed in the analysis
b Hazard ratio estimates risk increase per 10 units of the factor
c Wald test for the overall effect of self-rated health: p-value = 0.012 (model I); p-value = 0.048 (model II)
* p < 0.05, **p ≤ 0.01, ***p ≤ 0.001
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Page 9 of 12physical activity in the prediction of morbidity and mor-
tality [28]. The physiological effect of exercise probably
acts through some of the examined risk factors, but the
hazard ratio for physical activity was not weakened in
the multivariate models in Tables 1 and 3.
Our results on SRH and physical activity may have
been influenced by heterogeneity among our patients in
their susceptibility to dying, also known as frailty [29].
Undiagnosed or even unascertainable conditions may
have contributed to precipitate the diabetes diagnosis,
and these conditions may be associated with both poor
SRH or low physical activity and high risk of death. We
approached the unobserved heterogeneity in three addi-
tional analyses which did not substantially affect our
results (Tables 4, 5 and 6).
Blood glucose, lipids and blood pressure have been
found to predict mortality in population-based studies
of people with known diabetes [1,2] but not in the
Table 6 Predictors of all-cause mortality in patients who died within 3 years of diabetes diagnosis or after this time
Died within 3 years of diabetes
diagnosis
n = 153
Died 3 years after diabetes diagnosis
or later
n = 145
Heterogeneity, p-
value
c
Sex Women 1 1
Men 1.51 (1.15-2.00)** 1.77 (1.34-2.35)*** 0.30
Age at diabetes diagnosis
(years)
0.88 (0.78-1.01) 0.88 (0.77-1.01) 0.50
Living alone No 1 1
Yes 0.99 (0.73-1.34) 1.19 (0.86-1.64) 0.31
Education Higher 1 1
Basic 0.86 (0.61-1.23) 1.20 (0.84-1.71) 0.014
Diagnostic plasma glucose
(mmol/l)
a
1.08 (0.77-1.53) 1.16 (0.83-1.64) 0.11
Fasting triglycerides (mmol/l) 1.02 (0.98-1.06) 1.02 (0.97-1.07) 0.95
Total cholesterol (mmol/l) 0.91 (0.83-0.99)* 0.94 (0.86-1.03) 0.079
Urinary albumin (mg/l)
a 1.14 (1.04-1.24)** 1.18 (1.08-1.30)*** 0.24
Body mass index (kg/m
2) 0.97 (0.95-1.00)* 0.98 (0.96-1.01) 0.043
Resting heart rate (beats/min)
b
1.17 (1.06-1.28)*** 1.20 (1.09-1.31)*** 0.081
Systolic blood pressure
(mmHg)
b
0.95 (0.90-1.00) 0.96 (0.91-1.02) 0.047
Physical activity Active 1 1
Sedentary 1.29 (0.94-1.75) 1.99 (1.47-2.70)*** 0.020
Smoking Never 1 1
Former 1.42 (0.97-2.08) 2.05 (1.42-2.94)***
Current 1.36 (0.95-1.93) 1.68 (1.18-2.40)** 0.12
Self-rated health Excellent 1 1
Good 1.17 (0.71-1.92) 1.48 (0.90-2.43)
Fair 1.59 (1.02-2.48)* 1.90 (1.21-2.99)**
Poor/Very
poor
2.05 (1.14-3.68)* 2.96 (1.66-5.27)*** 0.31
Cardiovascular disease No 1 1
Yes 1.96 (1.47-2.61)*** 2.35 (1.73-3.19)*** 0.29
Diabetic retinopathy No 1 1
Yes 0.84 (0.39-1.80) 1.41 (0.71-2.80) 0.32
Peripheral neuropathy No 1 1
Yes 0.94 (0.65-1.36) 1.47 (1.04-2.10)* 0.062
Cancer (former or present) No 1 1
Yes 1.51 (0.84-2.70) 2.29 (1.31-4.02)** 0.30
Values are hazard ratios (95% confidence intervals) with p-values from univariate Cox regression analyses with separate hazard ratios for deaths within 3 years of
diabetes diagnosis and after this time. n = 1,025 for survivors.
a The characteristic is log-transformed in the analysis
b Hazard ratio estimates risk increase per 10 units of the factor
c p-values from the Wald test for the null-hypothesis that the hazard ratios for deaths < 3 years and ≥ 3 years after diabetes diagnosis are the same
*p < 0.05, **p ≤ 0.01, ***p ≤ 0.001
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and regression dilution bias [30], which is particularly
relevant for biochemical and clinical variables in the
physiologically disruptive non-equilibrium state of newly
diagnosed clinical diabetes, as well as frailty and differ-
ences in multivariate modelling. On the other hand, our
hazard ratios for blood glucose for example were on a
level with those from earlier studies [1] although non-
significant. Since our patient sample was established in
the early 90’s, screening for diabetes has been intensi-
fied. These initiatives to identify patients earlier in the
natural history of diabetes have probably decreased the
variability of many of the baseline variables measured in
our study. There is, however, no reason to suppose that
the causal patterns underlying the associations that we
have identified are different nowadays.
Conclusions
To conclude, we found that patients who rated their
health as less than excellent had increased 5-year mor-
tality, similar to that of patients with prevalent CVD,
even when biochemical, clinical and life-style variables
were controlled for. The patient seems to have a knowl-
edge about own health, which cannot be explained by
patient’s objective health status as it is described with
present-day technology [31]. This finding could motivate
doctors and other health practitioners to discuss percep-
tions of health with newly diagnosed diabetic patients
and be attentive to patients with suboptimal health rat-
ings. Our findings also confirm that life-style changes
and optimizing treatment are particularly relevant for
relatively young and inactive patients and those who
already have CVD or (micro)albuminuria at the time of
diabetes diagnosis.
Additional material
Additional file 1: The wording of selected patient questionnaires.
The wording of patient questionnaires about self-rated health, leisure
time physical activity, cohabitation status, education, and cancer.
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